|
US4882335A
(en)
*
|
1988-06-13 |
1989-11-21 |
Alko Limited |
Method for treating alcohol-drinking response
|
|
US6271239B1
(en)
*
|
1992-04-13 |
2001-08-07 |
Regents Of The University Of Minnesota |
Delta opioid receptor-selective benzylidene-substituted morphinans
|
|
US5352680A
(en)
*
|
1992-07-15 |
1994-10-04 |
Regents Of The University Of Minnesota |
Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
|
|
US5580876A
(en)
*
|
1992-09-21 |
1996-12-03 |
Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
|
|
USRE36547E
(en)
*
|
1992-09-21 |
2000-02-01 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
|
|
US6096756A
(en)
|
1992-09-21 |
2000-08-01 |
Albert Einstein College Of Medicine Of Yeshiva University |
Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
|
|
US5298622A
(en)
*
|
1993-05-12 |
1994-03-29 |
Regents Of The University Of Minnesota |
Spiroindane opiate analogs
|
|
US5457208A
(en)
|
1993-06-21 |
1995-10-10 |
Regents Of The University Of Minnesota |
Kappa opioid receptor antagonists
|
|
US5587381A
(en)
*
|
1995-03-27 |
1996-12-24 |
Sinclair; John D. |
Method for terminating methadone maintenance through extinction of the opiate-taking responses
|
|
WO1997018781A1
(en)
*
|
1995-11-20 |
1997-05-29 |
University Of Miami |
Method of treating nicotine dependence
|
|
US5878750A
(en)
*
|
1996-11-14 |
1999-03-09 |
Clemens; Anton H. |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
|
US5780479A
(en)
*
|
1997-04-04 |
1998-07-14 |
Regents Of The University Of Minnesota |
Use of opioid antagonists to treat impulse-control disorders
|
|
KR100417490B1
(ko)
|
1997-12-22 |
2004-02-05 |
유로-셀티크 소시에떼 아노뉨 |
오피오이드 제형의 남용을 방지하는 방법
|
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
|
PT1685839E
(pt)
|
1997-12-22 |
2013-07-08 |
Euro Celtique Sa |
Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
|
|
WO2001040269A2
(en)
*
|
1999-11-30 |
2001-06-07 |
Corixa Corporation |
Compositions and methods for therapy and diagnosis of breast cancer
|
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
|
AU776904B2
(en)
|
2000-02-08 |
2004-09-23 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
|
US20040024004A1
(en)
*
|
2001-05-04 |
2004-02-05 |
Sherman Barry M. |
Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
|
|
US6846831B2
(en)
|
2000-08-15 |
2005-01-25 |
Cpd, Llc |
Method of treating the syndrome of lipodystrophy
|
|
US6528520B2
(en)
*
|
2000-08-15 |
2003-03-04 |
Cpd, Llc |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
|
US6262062B1
(en)
*
|
2000-08-15 |
2001-07-17 |
Cpd, Llc |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
|
DE60238756D1
(de)
|
2001-05-11 |
2011-02-10 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
|
US7879211B2
(en)
*
|
2001-07-13 |
2011-02-01 |
Arkray, Inc. |
Analyzing instrument, lancet-integrated attachment for concentration measuring device provided with analyzing instrument, and body fluid sampling tool
|
|
WO2003007802A2
(en)
*
|
2001-07-18 |
2003-01-30 |
Euro-Celtique, S.A. |
Pharmaceutical combinations of oxycodone and naloxone
|
|
US20030044458A1
(en)
*
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
|
JP4504013B2
(ja)
|
2001-08-06 |
2010-07-14 |
ユーロ−セルティーク エス．エイ． |
放出可能な及び封鎖されたアンタゴニストを有するオピオイドアゴニスト製剤
|
|
AU2002324624A1
(en)
*
|
2001-08-06 |
2003-02-24 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
|
WO2003015783A1
(en)
*
|
2001-08-14 |
2003-02-27 |
Biotie Therapies Corporation |
Method of treating alcoholism or alcohol abuse
|
|
DE20308437U1
(de)
|
2002-04-05 |
2003-11-13 |
Euroceltique S.A., Luxemburg/Luxembourg |
Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
|
|
US7501433B2
(en)
*
|
2002-05-17 |
2009-03-10 |
Jenken Biosciences, Inc. |
Opioid and opioid-like compounds and uses thereof
|
|
US7923454B2
(en)
*
|
2002-05-17 |
2011-04-12 |
Jenken Biosciences, Inc. |
Opioid and opioid-like compounds and uses thereof
|
|
EP1509182A4
(en)
*
|
2002-05-31 |
2009-12-30 |
Titan Pharmaceuticals Inc |
IMPLANTABLE POLYMERS DEVICE FOR THE DELAYED RELEASE OF BUPRENORPHINE
|
|
EP2422775A3
(en)
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Sequestering subunit and related compositions and methods
|
|
MXPA05010450A
(es)
|
2003-03-31 |
2005-11-04 |
Titan Pharmaceuticals Inc |
Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina.
|
|
US20040202717A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
|
US20050038062A1
(en)
*
|
2003-04-14 |
2005-02-17 |
Burns Lindsay H. |
Methods and materials for the treatment of pain comprising opioid antagonists
|
|
MY135852A
(en)
*
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
|
US8017622B2
(en)
*
|
2003-05-16 |
2011-09-13 |
Jenken Biosciences, Inc. |
Opioid and opioid-like compounds and uses thereof
|
|
US20060009478A1
(en)
*
|
2003-10-15 |
2006-01-12 |
Nadav Friedmann |
Methods for the treatment of back pain
|
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
|
EP1702558A1
(en)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
|
SI2484346T1
(sl)
|
2006-06-19 |
2017-05-31 |
Alpharma Pharmaceuticals Llc |
Farmacevtski sestavki
|
|
CA2666846C
(en)
*
|
2006-10-20 |
2018-04-10 |
Cpd, Llc |
Method of restoring the incretin effect
|
|
US8623418B2
(en)
*
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
AU2008346870A1
(en)
*
|
2007-12-17 |
2009-07-16 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
|
EP2291380B1
(en)
*
|
2008-04-24 |
2011-09-07 |
Janssen Pharmaceutica N.V. |
Nalmefene prodrugs
|
|
US20110053971A1
(en)
*
|
2008-04-24 |
2011-03-03 |
Janssen Pharmaceutica Nv |
Nalmefene di-ester prodrugs
|
|
MY150600A
(en)
*
|
2008-07-07 |
2014-01-30 |
Euro Celtique Sa |
Use of opioid antagonists for treating urinary retention
|
|
PT2405915T
(pt)
|
2009-03-10 |
2019-01-29 |
Euro Celtique Sa |
Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona
|
|
US20140005217A1
(en)
*
|
2012-06-27 |
2014-01-02 |
H. Lundbeck A/S |
Nalmefene for reduction of alcohol consumption in specific target populations
|
|
WO2014170353A1
(en)
*
|
2013-04-17 |
2014-10-23 |
H. Lundbeck A/S |
Nalmefene for treatment of patients with sleep disorder
|
|
NZ716267A
(en)
|
2013-07-23 |
2017-05-26 |
Euro Celtique Sa |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
|
TW201625252A
(zh)
*
|
2014-04-22 |
2016-07-16 |
大塚製藥股份有限公司 |
藥物
|
|
WO2016073615A1
(en)
|
2014-11-07 |
2016-05-12 |
Regents Of The University Of Minnesota |
Salts and compositions useful for treating disease
|
|
AU2017253228B2
(en)
*
|
2016-04-22 |
2020-04-09 |
Taiwanj Pharmaceuticals Co., Ltd. |
Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease
|